All News
Filter News
Found 11,787 articles
-
HPV Vaccine Market: 5.73Bn by 2028, Human Papillomavirus Vaccine Market (Type, Dosage) Growing at 5% CAGR Lead by 9-Valent HPV Vaccine Segment, Global Analysis by The Insight Partners
5/26/2023
The Insight Partners published latest research study on “Human Papillomavirus (HPV) Vaccine Market Size, Share, Growth, Revenue, Trends, Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (9-Valent HPV Vaccine, Quadrivalent HPV Vaccine
-
Kidney Disease Market to Grow at 6.5% CAGR to be Worth $133.44Bn, Globally, by 2027 - Exclusive Report by The Insight Partners
5/26/2023
According to the new market research report "Kidney Disease Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product Type (Diagnosis, Treatment)
-
Asthma Drugs Market (Medications, Route of Administration) Reach $34.13Bn, by 2028 at 5% CAGR with Quick Relief Medications Segment Driving Growth During 2021-2028 | The Insight Partners
5/26/2023
The Insight Partners published latest research report on "Asthma Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Medications, Route of Administration, and Distribution Channels”,
-
Drug Delivery Market (Route of Administration, Distribution Channel) - Reach $3254.59Bn by 2028 at 7.7% CAGR with Topical Drug Delivery Segment Driving Growth During 2023 –2028 | The Insight Partners
5/24/2023
The Insight Partners published latest research report on "Drug Delivery Market Growth Report, Size, Share, Trends & Growth Forecast to 2028 - COVID-19 Impact and Global Analysis By Route of Administration, Distribution Channel and End User”, the global market size is expected to grow from USD 20,99,856.7 million in 2022 to USD 32,54,594.2 million by 2028; it is estimated to record a CAGR of 7.7% from 2023 to 2028.
-
Sanofi and Regeneron reported positive results for the anti-inflammatory drug in a chronic obstructive pulmonary disease trial. The companies hope to see approval before a 2024 read-out of a second trial.
-
G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel
5/22/2023
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the appointment of Monica Thomas as its General Counsel and Chief Compliance Officer.
-
Influenza Vaccines Market (Vaccine Type, Virus Type) - Reach $12.27Bn by 2028 at 7.4% CAGR with Quadrivalent Vaccine Segment Driving Growth During 2022–2028 | The Insight Partners
5/22/2023
The Insight Partners published latest research report on "Influenza Vaccines Market Size Report, Share, Trends, Growth, Demand & Forecast to 2028 - COVID-19 Impact and Global Analysis By Vaccine Type, Virus Type, Technology, Route of Administration, and Target Group”, the global market size is projected to reach USD 12,272.49 million by 2028 from USD 7,478.53 million in 2021
-
Sania Therapeutics launches to advance novel medicines for neural circuit dysfunction
5/17/2023
Sania Therapeutics launches today by unveiling its suite of proprietary patented platforms at the American Society of Gene & Cell Therapy (ASGCT) conference.
-
The U.S. Supreme Court’s denial of Teva Pharmaceuticals’ appeal could have broad ramifications for the wider generics industry, for which “skinny labeling” is a common and accepted practice.
-
Erasca Further Strengthens Business Leadership with Two Key Promotions
5/16/2023
Erasca, Inc. announced that David Chacko, M.D., previously chief financial officer of Erasca, has been promoted to the dual position of CFO and chief business officer, and Nik Chetwyn, Ph.D., previously senior vice president of operations of Erasca, has been promoted to chief operating officer, with each promotion being effective as of May 15, 2023.
-
Gastrointestinal Drugs Market Value Worth $71.30 Billion, Globally, by 2027 at 4.9% CAGR | The Insight Partners
5/15/2023
The Insight Partners published latest research report on "Gastrointestinal Drugs Market Sales Report, Size, Share, Trends, Growth and Demand Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Class; Route of Administration; Application; Distribution Channel and Geography" the global market size is projected to reach USD 71,300.28 million by 2027 from USD 49,043.38 million in 2019;
-
[Market Report] Allergy Treatment Market Growth to Hit USD 35.81 Billion, Globally, by 2028 - The Insight Partners
5/15/2023
The Insight Partners published latest research report on "Allergy Treatment Market Size Report, Share, Trends, Growth & Demand Forecast to 2028 - COVID-19 Impact and Global Analysis By Allergy Type and Treatment”, the global market share is projected to reach USD 35,812.33 million by 2028 from USD 21,160.92 million in 2020; it is estimated to grow at a CAGR of 6.9% from 2021 to 2028.
-
Preliminary trial results show the GSK five-in-one meningitis vaccine is immunologically effective against the most common strains, as the FDA decision date for Pfizer’s candidate looms.
-
SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update
5/11/2023
SCYNEXIS, Inc. announced financial results for the first quarter ended March 31, 2023.
-
Bausch Health Observes Mental Health Awareness Month
5/10/2023
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is proud to recognize May as Mental Health Awareness Month by continuing efforts that highlight the importance of educating and supporting those with mental health care needs.
-
TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
5/10/2023
TScan Therapeutics, Inc. (Nasdaq: TCRX) (“TScan” or the “Company”) today reported financial results and provided a corporate update for the first quarter ended March 31, 2023.
-
Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
5/10/2023
Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announced financial results for the quarter ended March 31, 2023, and highlighted recent corporate accomplishments.
-
Travel Vaccines Market Revenue to Reach $ 5.91 Billion, Globally, by 2028 with 9.8% CAGR | The Insight Partners
5/9/2023
The Insight Partners published latest research report on "Travel Vaccines Market Size Report, Share, Trends & Growth Forecast to 2028 - COVID-19 Impact and Global Analysis By Product and Application”,
-
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
5/8/2023
CureVac N.V. today announced that the first participant was dosed in the Phase 1 part of a combined Phase 1/2 study of multivalent, modified mRNA seasonal flu vaccine candidates, developed in collaboration with GSK.
-
As the COVID-19 market dries up, Moderna looks to FDA approval of its other vaccines including a 2024 commercial launch of its investigational RSV vaccine for older adults.